Atopic Dermatitis

Peter Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois, discusses the 2023 Society for Pediatric Dermatology Meeting held in Asheville, North Carolina, and what pearls to consider following the atopic dermatitis panel he took part in.

In her presentation ‘Treatment of Eczema in Pediatric Patients Under 12 Years,’ Dr. Garza-Mayers spoke on considerations for atopic dermatitis management.

A healthy 2-year-old boy with atopic dermatitis developed intermittent flares of eczematous patches on his legs with dramatic sparing below the sock line following meals. What is the diagnosis?

The once-daily topical cream for the treatment of atopic dermatitis (AD) has demonstrated positive topline results in 2 phase 3 studies in adults and children aged 2 years and up. According to Dermavant, a supplemental new drug application (sNDA) filed with the FDA is anticipated in Q1 of 2024.

In identical phase 3 trials, roflumilast demonstrated topline positive results, reducing itch in children and adults with mild to moderate AD.

In a phase 3 clinical trial, dupilumab met both its primary and key secondary endpoints, demonstrating efficacy as a potential treatment for atopic hand and foot dermatitis.

At the 44th National Association of Pediatric Nurse Practitioners Conference, methods of treating atopic dermatitis were discussed.

A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.

Results from a recent phase 3 clinical trial demonstrated topline safety and efficacy results for tapinarof cream, 1% (VTAMA; Dermavant) as a potential treatment for atopic dermatitis in patients 2 years and older.

A supplemental New Drug Application (sNDA) for abrocitinib (CIBINQO; Pfizer) in adolescents has been approved by the US Food and Drug Administration.

A recent study highlighted new information on racial disparities in health care for Black and Hispanic pediatric patients with atopic dermatitis.

Brittany Craiglow, MD, and Angela J Lamb, MD, share closing thoughts on the role of pediatricians and emerging treatments in the pipeline for pediatric AD.

Expert dermatologists review the use of dupilumab for treatment of pediatric AD, and how topical and injectable medication can impact a patient’s lifestyle.

Angela Lamb, MD, shares her approach to treatment selection for pediatric patients with AD.

Brittany Craiglow, MD, and Angela J Lamb, MD, share initial case impressions of a 7-year-old female patient with AD and discuss the key role of parents in disease management.

Drs Brittany Craiglow and Angela Lamb provide insight on how they address access to care issues that arise for patients with pediatric AD.

Expert dermatologists discuss the role of a multidisciplinary care team in treating pediatric AD and the modes of communication between specialists and pediatricians.

Brittany Craiglow, MD, and Angela J Lamb, MD, review a pediatric patient’s journey to diagnosis and treatment of AD.

Brittany Craiglow, MD, and Angela J Lamb, MD, discuss the varying presentation of atopic dermatitis (AD) among different skin types and skin color, as well as the challenges in gauging disease severity.

A recent article highlighted multiple therapies for treating atopic dermatitis, including many which do not require a prescription.

A recent article highlighted multiple forms of treatment for atopic dermatitis, detailing their benefits and adverse events.

Adults with atopic dermatitis saw improved symptoms when taking dupilumab compared to placebo, regardless of the age when they first presented with the condition.

Research suggested no significant relationship between peanut sensitivity and AD severity as measured by two scores, although the study was acknowledged to have a smaller population due to pandemic restrictions.

Recently announced data from the INTEGUMENT-1 phase 3 clinical trial demonstrated positive safety and efficacy results for atopic dermatitis patients 6 years and older treated with roflumilast cream (Arcutis Biotherapeutics).

New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.

Dermavant Sciences recently announced positive results for VTAMA (tapinarof cream, 1%) for treatment of atopic dermatitis in children aged as young as 2 years.

New research suggests the sleep quality of caregivers and patients with atopic dermatitis (inadequately-controlled with topical therapies) may improve with dupilumab treatment.

A review examined the ways in which costs can be reduced for patients with varying types of atopic dermatitis.

In a recent article, researchers discussed current atopic dermatitis treatments, along with the need for safe and effective long-term treatments.

Improvements in atopic dermatitis symptoms were seen in children taking dupilumab, with minimal adverse events.